On October 16, 2024, the Society for Immunotherapy of Cancer (SITC) held the fifth webinar in the new series "Increasing Access to IO: A Global Webinar Series". The recording of the fifth webinar "Monitoring Response to Cancer Immunotherapy: Increasing Access to IO" is available below.sdaf
Webinar Moderator
Webinar Faculty
Program Information
The Global Access and Impact Committee, in collaboration with the Diversity, Equity, and Inclusion Committee, is pleased to launch SITC’s first educational program crafted specifically for international audiences, titled “Increasing Access to IO: A Global Webinar Series”. These free digital events will provide a forum for physicians around the globe to discuss challenges and solutions related to critical topics, such as defining biomarkers for PD-L1 positive patients, biomarker assessment for tumor response, cellular therapy and checkpoint inhibitor administration, tumor mutational burden (TMB) and more. Featuring doctors from varying settings around the world, this webinar series offers a unique opportunity to learn about different solutions to immunotherapy application and the barriers currently impeding equitable access to IO. The objective of this webinar series is to create a platform for international stakeholders to discuss critical topics and challenges they face when treating patients with immunotherapy, with a key goal of providing education and bringing awareness to the barriers currently impeding equitable access to IO around the globe.
sdf
To register for the full series click here.
asd
#PresentationSlides#RecordedWebinar#2024
This library resource entry requires a SITC CONNECT account. Click the Sign In button at the top of this page, otherwise click here to create a FREE SITC CONNECT.
With a free SITC CONNET account, you can begin accessing hundreds of cancer immunotherapy resources in the SITC CONNECT Archive and Resource Libraries. Once your account is created, return to this page, refresh, and a download link should appear.
The SITC connectED education portal is supported by independent educational grants from AstraZeneca Pharmaceuticals LP and Merck & Co., Inc.
Join
Renew
Member Directory
My Profile
Volunteer
Support SITC
Job Board
Contact Us